ClinicalTrials.gg
CompletedNCT01257815RELIGHTUpdated Sep 30, 2014

Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment

A Phase 4 interventional study of Ranibizumab in Diabetic Retinopathy and Macular Oedema, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
111
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.

Enrollment
10th of 34
111 · median 57
Started
2011
with 4 others
Phase 4
10 of 34
1 open now
Registered
10th of 34
by date
Lead sponsor
6 of 34
Novartis Pharmaceuticals

Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 10th largest by enrollment, is one of 5 that started in 2011, is one of 10 in phase 4, and was the 10th registered.

Diabetic Retinopathy

781 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing ranibizumab in Diabetic Retinopathy, or all of them as a file.
02

Study summary

This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the first three months then two-monthly follow-up until 18 months in patients with visual impairment due to diabetic macular oedema.The aim of the study is to determine if this treatment regimen is effective and safe in these patients.

03

Conditions studied

  • Diabetic Retinopathy
  • Macular Oedema

Keywords

  • Diabetes mellitus
  • Diabetic retinopathy
  • Macular oedema
  • Visual acuity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type 1 or Type 2 diabetes mellitus.
  • Patients with visual impairment due to focal or diffuse diabetic macular oedema (DMO), and not other causes, in at least one eye who are eligible for laser treatment in the opinion of the investigator.
  • Best Corrected Visual Acuity between 78 and 24 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS)-like grading charts (approximate Snellen equivalent of 20/32 to 20/320).
  • Increased central retinal thickness which, in the opinion of the investigator, is due to DMO.

Exclusion criteria

Exclusion Criteria:

  • Concomitant conditions in the study eye that could prevent the improvement of visual acuity on study treatment.
  • Active intraocular inflammation (grade trace or above) or infection in either eye at enrollment.
  • History of uveitis in either eye at any time.
  • Structural damage within 0.5 disc diameters of the centre of the macular in the study eye likely to preclude improvement in visual acuity following resolution of macular oedema.
  • Planned medical or surgical intervention during the 18-month study period.
  • Uncontrolled glaucoma in either eye at screening.
  • Blood pressure systolic > 160 mmHg or diastolic > 100 mmHg at screening.
  • Ocular conditions in the study eye that require chronic concomitant therapy with topical ocular or systemically administered .
  • History of acute thromboembolic event within 4 months of screening.
  • Untreated diabetes mellitus.
  • Evidence of advanced, severe or unstable concomitant disease or its treatment which may interfere with evaluations or put the patient at special risk.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5mg

    Drug: Ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. The change in mean Best Corrected Visual Acuity (BCVA)

    Time frame: Baseline to 12 months

Secondary outcomes

  1. The change in mean Best Corrected Visual Acuity (BCVA)

    Time frame: Baseline to 18 months

  2. Occurrence of ocular and systemic adverse events

    Time frame: Baseline to 18 months

  3. Time course of changes in BCVA

    Time frame: From 6 to 12 and 18 months

  4. Time course of changes in central retinal thickness

    Time frame: From baseline and 6 months to 12 and 18 months

  5. Proportion of patients with 10 and 15 letter improvement or loss in BCVA

    Time frame: From baseline to 12 and 18 months

07

Study locations

15 sites
  • Novartis Investigative Site
    Torquay, Devon, TQ2 7AA, United Kingdom
  • Novartis Investigative Site
    Ayr, KA6 6DX, United Kingdom
  • Novartis Investigative Site
    Belfast, BT12 6BA, United Kingdom
  • Novartis Investigative Site
    Birmingham, B9 5SS, United Kingdom
  • Novartis Investigative Site
    Cardiff,, CF14 4XW, United Kingdom
  • Novartis Investigative Site
    Colchester, CO3 3NB, United Kingdom
  • Novartis Investigative Site
    Fife, KY12 OSU, United Kingdom
  • Novartis Investigative Site
    Great Yarmouth, NR31 6LA, United Kingdom
  • Novartis Investigative Site
    Hull, HU3 2JZ, United Kingdom
  • Novartis Investigative Site
    Liverpool, L7 8XP, United Kingdom
  • Novartis Investigative Site
    London, E11 1NR, United Kingdom
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    Rugby, CV22 5PX, United Kingdom
  • Novartis Investigative Site
    Uxbridge, UB8 3NN, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
08

References and documents

Publications

  • Pearce I, Banerjee S, Burton BJ, Chakravarthy U, Downey L, Gale RP, Gibson J, Pagliarini S, Patel J, Sivaprasad S, Andrews C, Brittain C, Warburton J; RELIGHT Study Group. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Ophthalmology. 2015 Sep;122(9):1811-9. doi: 10.1016/j.ophtha.2015.05.038. Epub 2015 Jul 3. PubMed 26150052 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2010
First posted
Dec 10, 2010
Start
Jan 2011
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
Sep 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01257815
Responsible party
Sponsor
First posted
Dec 10, 2010
Start date
Jan 2011
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Sep 30, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion